Matrix to Predict Rapid Radiographic Progression of Early Rheumatoid Arthritis Patients from the Community Treated with Methotrexate or Leflunomide: Results from the ESPOIR Cohort

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2012 Nov 21

PMID 23164197

Citations 23

Authors

Bruno Fautrel

Benjamin Granger

Bernard Combe

Alain Saraux

Francis Guillemin

Xavier Le Loet

Affiliations

Soon will be listed here.

Abstract

Introduction: Early rheumatoid arthritis (RA) patients may show rapid radiographic progression (RRP) despite rapid initiation of synthetic disease-modifying anti-rheumatic drugs (DMARDs). The present study aimed to develop a matrix to predict risk of RRP despite early DMARD initiation in real life settings.

Methods: The ESPOIR cohort included 813 patients from the community with early arthritis for < 6 months; 370 patients had early RA and had received methotrexate or leflunomide during the first year of follow-up. RRP was defined as an increase in the van der Heijde-modified Sharp score (vSHS) ≥ 5 points at 1 year. Determinants of RRP were examined first by bivariate analysis, then multivariate stepwise logistic regression analysis. A visual matrix model was then developed to predict RRP in terms of patient baseline characteristics.

Results: We analyzed data for 370 patients. The mean Disease Activity Score in 28 joints was 5.4 ± 1.2, 18.1% of patients had typical RA erosion on radiographs and 86.4% satisfied the 2010 criteria of the American College of Rheumatology/European League Against Rheumatism. During the first year, mean change in vSHS was 1.6 ± 5.5, and 41 patients (11.1%) showed RRP. A multivariate logistic regression model enabled the development of a matrix predicting RRP in terms of baseline swollen joint count, C-reactive protein level, anti-citrullinated peptide antibodies status, and erosions seen on radiography for patients with early RA who received DMARDs.

Conclusions: The ESPOIR matrix may be a useful clinical practice tool to identify patients with early RA at high risk of RRP despite early DMARD initiation.

Citing Articles

Comparative analysis of clinical profile, therapeutic management, and clinical prognosis of patients with seropositive or seronegative rheumatoid arthritis following the introduction of a first targeted therapy in a real-life setting.

Angelozzi L, Gillibert A, Brevet P, Grosjean J, Darmoni S, Jouen F Clin Rheumatol. 2025; .

PMID: 40063232 DOI: 10.1007/s10067-025-07390-3.

Increasing trend of radiographic features of knee osteoarthritis in rheumatoid arthritis patients before total knee arthroplasty.

Takeda R, Matsumoto T, Maenohara Y, Omata Y, Inui H, Nagase Y Sci Rep. 2022; 12(1):10452.

PMID: 35729263 PMC: 9213507. DOI: 10.1038/s41598-022-14440-2.

Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing Epitopes of Its γ Chain One of Which Is Not Cross Reactive With Anti-Citrullinated Protein Antibodies.

Brevet P, Lattard C, Guillou C, Rottenberg P, Fardellone P, Le-Loet X Front Immunol. 2021; 12:733511.

PMID: 34691039 PMC: 8529038. DOI: 10.3389/fimmu.2021.733511.

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M Ann Rheum Dis. 2021; 81(1):20-33.

PMID: 34407926 PMC: 8761998. DOI: 10.1136/annrheumdis-2021-220973.

Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study.

Rydell E, Forslind K, Nilsson J, Karlsson M, Akesson K, Jacobsson L Arthritis Res Ther. 2021; 23(1):27.

PMID: 33446222 PMC: 7809738. DOI: 10.1186/s13075-020-02413-7.

References

van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Coster L, Waltbrand E . Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009; 374(9688):459-66. DOI: 10.1016/S0140-6736(09)60944-2. View

van der Kooij S, le Cessie S, Goekoop-Ruiterman Y, de Vries-Bouwstra J, van Zeben D, Kerstens P . Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2008; 68(7):1153-8. DOI: 10.1136/ard.2008.093294. View

Fransen J, Moens H, Speyer I, Van Riel P . Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005; 64(9):1294-8. PMC: 1755664. DOI: 10.1136/ard.2004.030924. View

van der Heijde D . Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995; 34 Suppl 2:74-8. View

Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson I . Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2010; 70(3):469-75. DOI: 10.1136/ard.2010.139212. View

Emery P, Breedveld F, Dougados M, Kalden J, Schiff M, Smolen J . Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002; 61(4):290-7. PMC: 1754044. DOI: 10.1136/ard.61.4.290. View

Grigor C, Capell H, Stirling A, McMahon A, Lock P, Vallance R . Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004; 364(9430):263-9. DOI: 10.1016/S0140-6736(04)16676-2. View

Pincus T, Gibofsky A, Weinblatt M . Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum. 2002; 46(4):851-4. DOI: 10.1002/art.10202. View

Boers M, Verhoeven A, Markusse H, van de Laar M, Westhovens R, van Denderen J . Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997; 350(9074):309-18. DOI: 10.1016/S0140-6736(97)01300-7. View

10.

Prevoo M, van t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44-8. DOI: 10.1002/art.1780380107. View

11.

Le Loet X, Berthelot J, Cantagrel A, Combe B, De Bandt M, Fautrel B . Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis. 2005; 65(1):45-50. PMC: 1797976. DOI: 10.1136/ard.2005.035436. View

12.

Finckh A, Bansback N, Marra C, Anis A, Michaud K, Lubin S . Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009; 151(9):612-21. DOI: 10.7326/0003-4819-151-9-200911030-00006. View

13.

Visser H, le Cessie S, Vos K, Breedveld F, Hazes J . How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002; 46(2):357-65. DOI: 10.1002/art.10117. View

14.

van der Kooij S, de Vries-Bouwstra J, Goekoop-Ruiterman Y, van Zeben D, Kerstens P, Gerards A . Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007; 66(10):1356-62. PMC: 1994290. DOI: 10.1136/ard.2006.066662. View

15.

Rezaei H, Saevarsdottir S, Forslind K, Albertsson K, Wallin H, Bratt J . In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis. 2011; 71(2):186-91. DOI: 10.1136/annrheumdis-2011-200038. View

16.

Allaart C, Goekoop-Ruiterman Y, de Vries-Bouwstra J, Breedveld F, Dijkmans B . Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol. 2006; 24(6 Suppl 43):S-77-82. View

17.

Svensson B, Schaufelberger C, Teleman A, Theander J . Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. Rheumatology (Oxford). 2000; 39(9):1031-6. DOI: 10.1093/rheumatology/39.9.1031. View

18.

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

19.

Visser K, Katchamart W, Loza E, Martinez-Lopez J, Salliot C, Trudeau J . Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in.... Ann Rheum Dis. 2008; 68(7):1086-93. PMC: 2689523. DOI: 10.1136/ard.2008.094474. View

20.

van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C . Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2010; 63(1):65-78. DOI: 10.1002/acr.20338. View